Metagenomi to Present Preclinical Data Supporting New Collaboration Target of APOC3 with Ionis Pharmaceuticals at Upcoming Nature Conference
Rhea-AI Summary
Metagenomi (Nasdaq: MGX) will present new preclinical data supporting APOC3 as the third collaboration target with Ionis Pharmaceuticals at the Nature Conference “Cracking the Code: Nucleic Acid Medicines Coming of Age” on Dec 8-10, 2025 in Boston.
Presentation title: CRISPR/Cas-mediated APOC3 Knockout as a One-time Treatment for Severe Hypertriglyceridemia. Presenter: Alan Brooks, PhD, Senior Vice President of Research at Metagenomi. Date/time: Monday, December 8, 2025 at 2:45 p.m. EST. The talk covers preclinical evidence supporting the APOC3 target in the Ionis collaboration.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, MGX declined 8.57%, reflecting a notable negative market reaction. Argus tracked a trough of -2.4% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $6M from the company's valuation, bringing the market cap to $62M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
MGX is up 1.68% while several peers such as ACET (-2.86%), VANI (-6.08%), and IGMS (-2.31%) declined. NRXP was flat intraday and showed a -2.45% reaction to its own conference news, and OSTX gained 1.5%, suggesting stock-specific rather than sector-driven dynamics for MGX.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 01 | Conference presentation | Neutral | -8.6% | Announcement of APOC3 preclinical data presentation at a Nature conference. |
| Nov 17 | Conference appearance | Neutral | -2.3% | Jefferies Global Healthcare Conference presentation scheduling and webcast details. |
| Nov 11 | Earnings results | Positive | +2.3% | Q3 2025 results, MGX-001 progress, cash runway into 4Q 2027, leadership changes. |
| Nov 11 | Clinical data update | Positive | +2.3% | Preclinical MGX-001 hemophilia A data showing curative FVIII activity and dose strategy. |
| Aug 12 | Earnings results | Positive | +3.2% | Q2 2025 results, strong liquidity and durable FVIII activity in MGX-001 program. |
Conference and presentation announcements for MGX have often seen negative next-day moves, while data-rich clinical and earnings updates with positive program or financial details have tended to produce modest gains.
Over the last six months, Metagenomi has mixed event-driven reactions. Conference and presentation announcements on Nov 17, 2025 and Dec 1, 2025 drew negative next-day moves, despite being neutral-to-positive visibility events. In contrast, Q2 and Q3 2025 earnings updates and MGX-001 preclinical data in hemophilia A, reported on Aug 12 and Nov 11, 2025, coincided with modest gains of 2–3%. Today’s APOC3 preclinical presentation continues the theme of showcasing pipeline breadth alongside an already capital-intensive R&D profile.
Market Pulse Summary
The stock moved -8.6% in the session following this news. A negative reaction despite neutral-to-positive scientific visibility would fit the pattern seen around past conference news, including the -8.57% move after a similar presentation announcement on Dec 1, 2025. While the APOC3 update highlights additional pipeline depth, investors have also been contending with a Q3 2025 net loss of $20.4M and collaboration revenue that declined year over year. These factors, combined with a price below the $1.93 200-day average, could reinforce caution.
Key Terms
genome editing medical
nucleic acid medicines medical
crispr/cas medical
hypertriglyceridemia medical
AI-generated analysis. Not financial advice.
EMERYVILLE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that the Company will present new preclinical data supporting the third target, APOC3, in its collaboration with Ionis Pharmaceuticals at the Nature Conference “Cracking the Code: Nucleic Acid Medicines Coming of Age” taking place December 8-10, 2025, in Boston, MA.
Nature Conference “Cracking the Code: Nucleic Acid Medicines Coming of Age”
Title: CRISPR/Cas-mediated APOC3 Knockout as a One-time Treatment for Severe Hypertriglyceridemia
Presenters: Alan Brooks, PhD, Senior Vice President of Research at Metagenomi
Date/time: Monday, December 8, 2025, at 2:45 p.m. EST
About Metagenomi
Metagenomi is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The Company was founded on the science of metagenomics, the study of genetic materials recovered from the natural environment, to discover and develop a suite of novel editing tools potentially capable of correcting any type of genetic mutation found anywhere in the human genome. The Company focuses on high value programs in disease indications with well-understood biology and clearly defined clinical development and regulatory pathways. Going forward, the Company intends to continue to expand its pipeline by leveraging its proprietary genetic editing capabilities in site specific deletion, integration and correction.
MGX-001, the Company’s lead, wholly-owned development program in hemophilia A, has demonstrated a preclinical profile potentially competitive with best-in-class treatment options, including targeted genome editing and durable gene expression in a one-time treatment. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A. The Company is also currently pursuing other secreted protein deficiencies leveraging the MGX-001 site-specific genome integration system and partnered assets targeting cardiometabolic diseases. For more information, please visit https://metagenomi.co.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions include, but are not limited to, any statements relating to our product development programs, including the timing of and our ability to conduct IND-enabling studies and make regulatory filings such as INDs, expectations regarding MGX-001, including the preclinical profile being potentially competitive with best-in-class treatment options and timing to submit the IND/CTA package, statements regarding the Company’s plans to prioritize its preclinical pipeline and potential for value creation and sustainable growth, statements regarding upcoming milestones including the nomination of development candidates, statements concerning the potential of therapies and product candidates, statements concerning the impact of the organizational restructuring, statements concerning our anticipated cash runway, and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition, and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of IND submissions and starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation and the current regulatory environment; patent and intellectual property matters; competition; the volatility of capital markets and other adverse macroeconomic factors; as well as other risks described in “Risk Factors,” in our most recent Form 10-K and other risk factors set forth from time to time in our filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Investor Contacts:
Stephen Jasper
Gilmartin Group
stephen@gilmartinir.com
or
Kiki Patel, PharmD
Gilmartin Group
kiki@gilmartinir.com
FAQ
What will Metagenomi (MGX) present about APOC3 at the Nature Conference on December 8, 2025?
When and where is Metagenomi's MGX presentation on APOC3 scheduled during the Nature Conference?
Who is presenting Metagenomi's MGX APOC3 data at the Dec 2025 Nature Conference?
What is the focus of Metagenomi and Ionis's collaboration referenced in the MGX announcement?
How does Metagenomi describe the potential therapy for APOC3 at the conference?
Will Metagenomi (MGX) present other collaboration details with Ionis at the Nature Conference?
